Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes
Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes Results From the Finnish Diabetes Prevention Study Christian Herder 1 , Markku Peltonen 2 , Wolfgang Koenig 3 , Ilka Kräft 1 , Sylvia Müller-Scholze 1 , Stephan Martin 1 , Timo Lakka 4 , Pirjo Ilanne-Parikka 5 , Joh...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 55; no. 8; pp. 2340 - 2346 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
American Diabetes Association
01.08.2006
|
Online Access | Get full text |
ISSN | 0012-1797 1939-327X |
DOI | 10.2337/db05-1320 |
Cover
Loading…
Abstract | Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes
Results From the Finnish Diabetes Prevention Study
Christian Herder 1 ,
Markku Peltonen 2 ,
Wolfgang Koenig 3 ,
Ilka Kräft 1 ,
Sylvia Müller-Scholze 1 ,
Stephan Martin 1 ,
Timo Lakka 4 ,
Pirjo Ilanne-Parikka 5 ,
Johan G. Eriksson 2 ,
Helena Hämäläinen 6 ,
Sirkka Keinänen-Kiukaanniemi 7 ,
Timo T. Valle 2 ,
Matti Uusitupa 8 ,
Jaana Lindström 2 ,
Hubert Kolb 1 ,
Jaakko Tuomilehto 2 9 10 and
for the Finnish Diabetes Prevention Study Group
1 German Diabetes Clinic, German Diabetes Center, Leibniz Center at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
2 Department of Epidemiology and Health Promotion, Diabetes and Genetic Epidemiology Unit, National Public Health Institute,
Helsinki, Finland
3 Department Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany
4 Department of Physiology, University of Kuopio, Kuopio, Finland
5 Diabetes Center of the Finnish Diabetes Association and the Research Unit of Tampere University Hospital, Tampere, Finland
6 Research Department, Social Insurance Institution, Turku, Finland
7 Department of Public Health Science and General Practice, University of Oulu, Oulu, Finland
8 Department of Clinical Nutrition, University of Kuopio, Kuopio, Finland
9 Department of Public Health, University of Helsinki, Helsinki, Finland
10 South Ostrobothnia Central Hospital, Seinäjoki, Finland
Address correspondence and reprint requests to Dr. Christian Herder, German Diabetes Clinic, German Diabetes Center, Auf’m
Hennekamp 65, 40225 Düsseldorf, Germany. E-mail: christian.herder{at}ddz.uni-duesseldorf.de
Abstract
The Finnish DPS (Diabetes Prevention Study) demonstrated that lifestyle intervention, aimed at increasing physical activity,
improving diet, and decreasing body weight, reduced the incidence of type 2 diabetes in individuals with overweight and impaired
glucose tolerance by 58%. Here, we studied which immunological markers at baseline predicted subsequent type 2 diabetes and
whether there are immunologically defined subsets of subjects who are more or less responsive to the protective effects of
lifestyle intervention. We randomly assigned 522 participants to a control group ( n = 257) or a lifestyle intervention group ( n = 265). Immunological parameters at baseline included high-sensitivity C-reactive protein (CRP), serum amyloid A, interleukin-6,
regulated on activation normal T-cell expressed and secreted (RANTES), macrophage migration inhibitory factor (MIF), and soluble
intercellular adhesion molecule. In the control group, CRP was the best immunological predictor for progression to overt type
2 diabetes. In the intervention group, progression to type 2 diabetes was significantly higher in subjects with the highest
RANTES concentrations and was lower in subjects with the highest MIF levels. Ratios of RANTES to MIF in the upper tertile
were highly predictive of incident type 2 diabetes in the intervention group ( P = 0.006), whereas the association was less pronounced in the control group ( P = 0.088). Thus, systemic concentrations of immune mediators appear to be associated with the progression to type 2 diabetes
and the prevention of type 2 diabetes by lifestyle changes.
CRP, C-reactive protein
DPS, Diabetes Prevention Study
HOMA, homeostasis model assessment
IGT, impaired glucose tolerance
IL, interleukin
KORA, Cooperative Health Research in the Region of Augsburg (Kooperative Gesundheitsforschung in der Region Augsburg)
MIF, macrophage migration inhibitory factor
OGTT, oral glucose tolerance test
RANTES, regulated on activation, normal T-cell expressed and secreted
SAA, serum amyloid A
sICAM, soluble intercellular adhesion molecule
Footnotes
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Accepted May 15, 2006.
Received October 11, 2005.
DIABETES |
---|---|
AbstractList | Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes
Results From the Finnish Diabetes Prevention Study
Christian Herder 1 ,
Markku Peltonen 2 ,
Wolfgang Koenig 3 ,
Ilka Kräft 1 ,
Sylvia Müller-Scholze 1 ,
Stephan Martin 1 ,
Timo Lakka 4 ,
Pirjo Ilanne-Parikka 5 ,
Johan G. Eriksson 2 ,
Helena Hämäläinen 6 ,
Sirkka Keinänen-Kiukaanniemi 7 ,
Timo T. Valle 2 ,
Matti Uusitupa 8 ,
Jaana Lindström 2 ,
Hubert Kolb 1 ,
Jaakko Tuomilehto 2 9 10 and
for the Finnish Diabetes Prevention Study Group
1 German Diabetes Clinic, German Diabetes Center, Leibniz Center at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
2 Department of Epidemiology and Health Promotion, Diabetes and Genetic Epidemiology Unit, National Public Health Institute,
Helsinki, Finland
3 Department Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany
4 Department of Physiology, University of Kuopio, Kuopio, Finland
5 Diabetes Center of the Finnish Diabetes Association and the Research Unit of Tampere University Hospital, Tampere, Finland
6 Research Department, Social Insurance Institution, Turku, Finland
7 Department of Public Health Science and General Practice, University of Oulu, Oulu, Finland
8 Department of Clinical Nutrition, University of Kuopio, Kuopio, Finland
9 Department of Public Health, University of Helsinki, Helsinki, Finland
10 South Ostrobothnia Central Hospital, Seinäjoki, Finland
Address correspondence and reprint requests to Dr. Christian Herder, German Diabetes Clinic, German Diabetes Center, Auf’m
Hennekamp 65, 40225 Düsseldorf, Germany. E-mail: christian.herder{at}ddz.uni-duesseldorf.de
Abstract
The Finnish DPS (Diabetes Prevention Study) demonstrated that lifestyle intervention, aimed at increasing physical activity,
improving diet, and decreasing body weight, reduced the incidence of type 2 diabetes in individuals with overweight and impaired
glucose tolerance by 58%. Here, we studied which immunological markers at baseline predicted subsequent type 2 diabetes and
whether there are immunologically defined subsets of subjects who are more or less responsive to the protective effects of
lifestyle intervention. We randomly assigned 522 participants to a control group ( n = 257) or a lifestyle intervention group ( n = 265). Immunological parameters at baseline included high-sensitivity C-reactive protein (CRP), serum amyloid A, interleukin-6,
regulated on activation normal T-cell expressed and secreted (RANTES), macrophage migration inhibitory factor (MIF), and soluble
intercellular adhesion molecule. In the control group, CRP was the best immunological predictor for progression to overt type
2 diabetes. In the intervention group, progression to type 2 diabetes was significantly higher in subjects with the highest
RANTES concentrations and was lower in subjects with the highest MIF levels. Ratios of RANTES to MIF in the upper tertile
were highly predictive of incident type 2 diabetes in the intervention group ( P = 0.006), whereas the association was less pronounced in the control group ( P = 0.088). Thus, systemic concentrations of immune mediators appear to be associated with the progression to type 2 diabetes
and the prevention of type 2 diabetes by lifestyle changes.
CRP, C-reactive protein
DPS, Diabetes Prevention Study
HOMA, homeostasis model assessment
IGT, impaired glucose tolerance
IL, interleukin
KORA, Cooperative Health Research in the Region of Augsburg (Kooperative Gesundheitsforschung in der Region Augsburg)
MIF, macrophage migration inhibitory factor
OGTT, oral glucose tolerance test
RANTES, regulated on activation, normal T-cell expressed and secreted
SAA, serum amyloid A
sICAM, soluble intercellular adhesion molecule
Footnotes
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Accepted May 15, 2006.
Received October 11, 2005.
DIABETES The Finnish DPS (Diabetes Prevention Study) demonstrated that lifestyle intervention, aimed at increasing physical activity, improving diet, and decreasing body weight, reduced the incidence of type 2 diabetes in individuals with overweight and impaired glucose tolerance by 58%. Here, we studied which immunological markers at baseline predicted subsequent type 2 diabetes and whether there are immunologically defined subsets of subjects who are more or less responsive to the protective effects of lifestyle intervention. We randomly assigned 522 participants to a control group (n = 257) or a lifestyle intervention group (n = 265). Immunological parameters at baseline included high-sensitivity C-reactive protein (CRP), serum amyloid A, interleukin-6, regulated on activation normal T-cell expressed and secreted (RANTES), macrophage migration inhibitory factor (MIF), and soluble intercellular adhesion molecule. In the control group, CRP was the best immunological predictor for progression to overt type 2 diabetes. In the intervention group, progression to type 2 diabetes was significantly higher in subjects with the highest RANTES concentrations and was lower in subjects with the highest MIF levels. Ratios of RANTES to MIF in the upper tertile were highly predictive of incident type 2 diabetes in the intervention group (P = 0.006), whereas the association was less pronounced in the control group (P = 0.088). Thus, systemic concentrations of immune mediators appear to be associated with the progression to type 2 diabetes and the prevention of type 2 diabetes by lifestyle changes. |
Author | Markku Peltonen Jaana Lindström Hubert Kolb Johan G. Eriksson Pirjo Ilanne-Parikka Sirkka Keinänen-Kiukaanniemi Matti Uusitupa Christian Herder Timo Lakka Jaakko Tuomilehto Wolfgang Koenig Stephan Martin Helena Hämäläinen Ilka Kräft Timo T. Valle Sylvia Müller-Scholze |
Author_xml | – sequence: 1 fullname: Christian Herder – sequence: 2 fullname: Markku Peltonen – sequence: 3 fullname: Wolfgang Koenig – sequence: 4 fullname: Ilka Kräft – sequence: 5 fullname: Sylvia Müller-Scholze – sequence: 6 fullname: Stephan Martin – sequence: 7 fullname: Timo Lakka – sequence: 8 fullname: Pirjo Ilanne-Parikka – sequence: 9 fullname: Johan G. Eriksson – sequence: 10 fullname: Helena Hämäläinen – sequence: 11 fullname: Sirkka Keinänen-Kiukaanniemi – sequence: 12 fullname: Timo T. Valle – sequence: 13 fullname: Matti Uusitupa – sequence: 14 fullname: Jaana Lindström – sequence: 15 fullname: Hubert Kolb – sequence: 16 fullname: Jaakko Tuomilehto |
BookMark | eNptkEtLxDAUhYOMOA9d-A-yFamTV5tkKeMTRhQcwV1Jm5uZyLQdmqj039syA4LIXZy7ON_lnjNFo7qpAaFzSq4Y53JuC5ImlDNyhCZUc51wJt9HaEIIZQmVWo7RNIQPQkjWzwka00xJnmk9QavXLkSofIkfq-qzBvwE1pvYtAGb2uKldxBitwW82Jh6DQH7GscN4JcWvqCOvqlx4_Cq2wFm-MabAiKEU3TszDbA2UFn6O3udrV4SJbP94-L62VSMkpJAtoZqwgnziohC0KdSMEoYlUqGFjBBGTKlIUWhRQqdZxZKQhIq_vXwQGfoYv93bJtQmjB5bvWV6btckryoZl8aCYfmum98z_e0kczBIit8dt_ics9sfHrzbdvIbeHfL9Lmuaq5wThP3CBdNE |
CitedBy_id | crossref_primary_10_1186_s12263_017_0580_4 crossref_primary_10_1007_s00108_007_1932_8 crossref_primary_10_1096_fj_202301357RR crossref_primary_10_1371_journal_pone_0182359 crossref_primary_10_1038_ijo_2016_35 crossref_primary_10_1007_s00125_007_0800_3 crossref_primary_10_3904_kjim_2021_174 crossref_primary_10_1016_j_numecd_2010_01_006 crossref_primary_10_1016_S1499_2671_07_13011_2 crossref_primary_10_1038_s41430_018_0223_x crossref_primary_10_1177_1559827607306433 crossref_primary_10_4155_fmc_10_281 crossref_primary_10_1007_s00011_010_0163_y crossref_primary_10_1093_ajcn_nqac170 crossref_primary_10_1016_j_genm_2009_01_002 crossref_primary_10_3892_mmr_2014_2341 crossref_primary_10_1111_j_1365_2265_2008_03315_x crossref_primary_10_4239_wjd_v15_i10_2041 crossref_primary_10_2217_bmm_2016_0359 crossref_primary_10_1016_j_neubiorev_2011_10_001 crossref_primary_10_14341_DM200418_10 crossref_primary_10_1007_s00103_009_0868_7 crossref_primary_10_3945_jn_110_132571 crossref_primary_10_1186_1755_8794_2_2 crossref_primary_10_1155_2022_8099382 crossref_primary_10_2337_dc07_0106 crossref_primary_10_3389_fgene_2022_1063519 crossref_primary_10_1053_j_ackd_2017_12_002 crossref_primary_10_1186_1475_2891_10_115 crossref_primary_10_1016_j_ijcard_2015_08_107 crossref_primary_10_1007_s11920_015_0618_5 crossref_primary_10_1155_2007_93573 crossref_primary_10_1177_0145721714521020 crossref_primary_10_1097_TP_0b013e3182a45283 crossref_primary_10_1177_1076029612467845 crossref_primary_10_1016_j_brainresbull_2012_10_002 crossref_primary_10_1007_s11428_007_0155_x crossref_primary_10_1002_14651858_CD003054_pub4 crossref_primary_10_1371_journal_pone_0006733 crossref_primary_10_1111_j_1467_789X_2008_00542_x crossref_primary_10_1097_HJH_0b013e3282861fc0 crossref_primary_10_1038_s43856_023_00363_0 crossref_primary_10_1111_j_1464_5491_2011_03513_x crossref_primary_10_1096_fj_09_147066 crossref_primary_10_1155_2010_610479 crossref_primary_10_1136_oem_2008_044917 crossref_primary_10_1002_dmrr_910 crossref_primary_10_1017_S0007114518003240 crossref_primary_10_1038_nrneph_2011_51 crossref_primary_10_1002_art_38918 crossref_primary_10_1017_S0007114509371676 crossref_primary_10_1186_1753_6561_6_S3_P28 crossref_primary_10_3390_jpm11020119 crossref_primary_10_1016_j_metabol_2012_07_009 crossref_primary_10_1097_MED_0b013e3280d5f7e9 crossref_primary_10_3109_10408363_2015_1092106 crossref_primary_10_3390_nu17030526 crossref_primary_10_1038_s41387_018_0046_9 crossref_primary_10_5694_j_1326_5377_2009_tb02317_x crossref_primary_10_1111_j_1753_4887_2009_00181_x crossref_primary_10_32345_USMYJ_4_134__2022_29_36 crossref_primary_10_1177_1741826711422990 crossref_primary_10_1002_dmrr_740 crossref_primary_10_1155_2017_1375342 crossref_primary_10_3390_ijms23158668 crossref_primary_10_1002_mnfr_200700030 crossref_primary_10_1007_s13668_023_00458_z crossref_primary_10_1016_j_tem_2018_07_003 crossref_primary_10_1136_bmjopen_2018_025524 crossref_primary_10_1016_j_jcjd_2013_07_029 crossref_primary_10_1002_pdi_1359 crossref_primary_10_1007_s00125_008_1243_1 crossref_primary_10_1016_j_humimm_2017_06_001 crossref_primary_10_2337_dc08_1980 crossref_primary_10_1016_S0140_6736_06_69826_7 crossref_primary_10_1152_ajprenal_00314_2016 |
Cites_doi | 10.2337/diabetes.53.3.693 10.1007/BF03402125 10.1191/1352458504ms1080oa 10.1002/(SICI)1520-7560(199901/02)15:1<47::AID-DMRR9>3.0.CO;2-J 10.1161/01.CIR.0000148980.87579.5E 10.1016/S0161-5890(02)00013-5 10.1073/pnas.94.9.4782 10.1007/s00125-002-0829-2 10.2337/diacare.26.12.3230 10.1161/hc0502.103331 10.2337/diabetes.51.5.1596 10.1016/S0006-291X(02)00648-4 10.1001/archinte.163.1.93 10.1161/01.CIR.0000149077.87074.DE 10.1016/S0140-6736(99)01046-6 10.1097/00041433-200410000-00009 10.1056/NEJMoa012512 10.2337/diabetes.51.4.1131 10.1001/jama.290.14.1884 10.1093/clinchem/45.12.2136 10.1056/NEJM200105033441801 10.1056/NEJM199406023302201 10.1161/01.ATV.21.6.968 10.2337/diacare.27.3.813 10.1007/s00125-005-1764-9 10.2337/diabetes.54.1.158 10.2337/diabetes.52.10.2532 10.1007/s001250051229 10.4049/jimmunol.172.7.4018 10.2337/diabetes.50.10.2384 10.1055/s-2005-858227 10.2337/diabetes.52.3.812 10.1001/jama.291.16.1978 10.1001/jama.286.3.327 10.1016/S0002-9149(00)01355-2 |
ContentType | Journal Article |
CorporateAuthor | for the Finnish Diabetes Prevention Study Group |
CorporateAuthor_xml | – name: for the Finnish Diabetes Prevention Study Group |
DBID | AAYXX CITATION |
DOI | 10.2337/db05-1320 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1939-327X |
EndPage | 2346 |
ExternalDocumentID | 10_2337_db05_1320 diabetes_55_8_2340 |
GroupedDBID | - 08R 0R 1AW 29F 2WC 3V. 4.4 53G 55 5GY 5RE 5RS 5VS 7RV 7X7 88E 88I 8AF 8AO 8C1 8F7 8FE 8FH 8FI 8FJ 8G5 8GL 8R4 8R5 AAQQT AAWTL AAYEP AAYJJ ABFLS ABOCM ABPTK ABUWG ACDCL ACGOD ACPRK ADACO ADBBV ADBIT AENEX AFFNX AFKRA AHMBA ALMA_UNASSIGNED_HOLDINGS AZQEC BAWUL BBAFP BBNVY BCR BCU BEC BENPR BES BHPHI BKEYQ BKNYI BLC BPHCQ BVXVI C1A CS3 DIK DU5 DWQXO E3Z EBS EDB EJD EX3 F5P FRP FYUFA GICCO GJ GNUQQ GUQSH GX1 H13 HCIFZ HZ IAG IAO IEA IHR INH INR IOF IPO J5H K-O K9- KM KQ8 L7B LK8 M0R M1P M2O M2P M2Q M5 M7P MBDVC O0- O9- OB3 OBH OK1 OVD P2P PADUT PCD PEA PQEST PQQKQ PQUKI PRINS PROAC PSQYO Q2X RHF RHI RPM S0X SJFOW SJN SV3 TDI WH7 WOQ WOW X7M XZ ZA5 ZGI ZY1 --- .55 .GJ .XZ 08P 0R~ 18M 354 6PF AAFWJ AAKAS AAYOK AAYXX ACGFO ADGHP ADZCM AEGXH AERZD AIAGR AIZAD ALIPV BTFSW CCPQU CITATION EMOBN HMCUK HZ~ ITC K2M M5~ N4W NAPCQ OHH PHGZM PHGZT TEORI TR2 UKHRP VVN W8F YFH YHG YOC ~KM |
ID | FETCH-LOGICAL-c2110-e9fad8030fd847b01f45ea80d8542ed424e68acb94b7485f32d740e7d9699efe3 |
ISSN | 0012-1797 |
IngestDate | Tue Jul 01 04:24:03 EDT 2025 Thu Apr 24 22:57:12 EDT 2025 Fri Jan 15 19:45:54 EST 2021 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c2110-e9fad8030fd847b01f45ea80d8542ed424e68acb94b7485f32d740e7d9699efe3 |
OpenAccessLink | https://diabetesjournals.org/diabetes/article-pdf/55/8/2340/384818/zdb00806002340.pdf |
PMID | 16873699 |
PageCount | 7 |
ParticipantIDs | crossref_primary_10_2337_db05_1320 highwire_diabetes_diabetes_55_8_2340 crossref_citationtrail_10_2337_db05_1320 |
ProviderPackageCode | RHF RHI CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20060801 2006-08-01 |
PublicationDateYYYYMMDD | 2006-08-01 |
PublicationDate_xml | – month: 08 year: 2006 text: 20060801 day: 01 |
PublicationDecade | 2000 |
PublicationTitle | Diabetes (New York, N.Y.) |
PublicationYear | 2006 |
Publisher | American Diabetes Association |
Publisher_xml | – name: American Diabetes Association |
References | 2022031208461028700_R24 2022031208461028700_R23 2022031208461028700_R22 2022031208461028700_R21 2022031208461028700_R28 2022031208461028700_R27 2022031208461028700_R26 2022031208461028700_R25 2022031208461028700_R9 2022031208461028700_R20 2022031208461028700_R19 2022031208461028700_R18 2022031208461028700_R13 2022031208461028700_R35 2022031208461028700_R12 2022031208461028700_R34 2022031208461028700_R11 2022031208461028700_R33 2022031208461028700_R10 2022031208461028700_R32 2022031208461028700_R17 2022031208461028700_R16 2022031208461028700_R15 2022031208461028700_R37 2022031208461028700_R14 2022031208461028700_R36 2022031208461028700_R31 2022031208461028700_R30 2022031208461028700_R4 2022031208461028700_R3 2022031208461028700_R2 2022031208461028700_R1 2022031208461028700_R8 2022031208461028700_R7 2022031208461028700_R6 2022031208461028700_R5 2022031208461028700_R29 |
References_xml | – ident: 2022031208461028700_R15 doi: 10.2337/diabetes.53.3.693 – ident: 2022031208461028700_R32 doi: 10.1007/BF03402125 – ident: 2022031208461028700_R37 doi: 10.1191/1352458504ms1080oa – ident: 2022031208461028700_R30 doi: 10.1002/(SICI)1520-7560(199901/02)15:1<47::AID-DMRR9>3.0.CO;2-J – ident: 2022031208461028700_R26 doi: 10.1161/01.CIR.0000148980.87579.5E – ident: 2022031208461028700_R34 doi: 10.1016/S0161-5890(02)00013-5 – ident: 2022031208461028700_R23 – ident: 2022031208461028700_R31 doi: 10.1073/pnas.94.9.4782 – ident: 2022031208461028700_R19 doi: 10.1007/s00125-002-0829-2 – ident: 2022031208461028700_R5 doi: 10.2337/diacare.26.12.3230 – ident: 2022031208461028700_R29 doi: 10.1161/hc0502.103331 – ident: 2022031208461028700_R12 doi: 10.2337/diabetes.51.5.1596 – ident: 2022031208461028700_R33 doi: 10.1016/S0006-291X(02)00648-4 – ident: 2022031208461028700_R14 doi: 10.1001/archinte.163.1.93 – ident: 2022031208461028700_R27 doi: 10.1161/01.CIR.0000149077.87074.DE – ident: 2022031208461028700_R8 doi: 10.1016/S0140-6736(99)01046-6 – ident: 2022031208461028700_R35 doi: 10.1097/00041433-200410000-00009 – ident: 2022031208461028700_R4 doi: 10.1056/NEJMoa012512 – ident: 2022031208461028700_R11 doi: 10.2337/diabetes.51.4.1131 – ident: 2022031208461028700_R1 doi: 10.1001/jama.290.14.1884 – ident: 2022031208461028700_R20 doi: 10.1093/clinchem/45.12.2136 – ident: 2022031208461028700_R3 doi: 10.1056/NEJM200105033441801 – ident: 2022031208461028700_R18 doi: 10.1056/NEJM199406023302201 – ident: 2022031208461028700_R28 doi: 10.1161/01.ATV.21.6.968 – ident: 2022031208461028700_R24 doi: 10.2337/diacare.27.3.813 – ident: 2022031208461028700_R25 doi: 10.1007/s00125-005-1764-9 – ident: 2022031208461028700_R7 doi: 10.2337/diabetes.54.1.158 – ident: 2022031208461028700_R6 doi: 10.2337/diabetes.52.10.2532 – ident: 2022031208461028700_R22 – ident: 2022031208461028700_R17 doi: 10.1007/s001250051229 – ident: 2022031208461028700_R36 doi: 10.4049/jimmunol.172.7.4018 – ident: 2022031208461028700_R9 doi: 10.2337/diabetes.50.10.2384 – ident: 2022031208461028700_R2 doi: 10.1055/s-2005-858227 – ident: 2022031208461028700_R13 doi: 10.2337/diabetes.52.3.812 – ident: 2022031208461028700_R16 doi: 10.1001/jama.291.16.1978 – ident: 2022031208461028700_R10 doi: 10.1001/jama.286.3.327 – ident: 2022031208461028700_R21 doi: 10.1016/S0002-9149(00)01355-2 |
SSID | ssj0006060 |
Score | 1.8123935 |
Snippet | Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes
Results From the Finnish Diabetes Prevention Study
Christian Herder 1 ,... The Finnish DPS (Diabetes Prevention Study) demonstrated that lifestyle intervention, aimed at increasing physical activity, improving diet, and decreasing... |
SourceID | crossref highwire |
SourceType | Enrichment Source Index Database Publisher |
StartPage | 2340 |
Title | Systemic Immune Mediators and Lifestyle Changes in the Prevention of Type 2 Diabetes |
URI | http://diabetes.diabetesjournals.org/content/55/8/2340.abstract |
Volume | 55 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVKJyFeEJ9iDJCFNgkJBRLbSZ1HKEMdYhNCnehbZMf2qFa1qGsfxk_gV3NvbSeh9GHwEqVpnKq5R-d-2PeYkEOW6UxxwRLOFU-EyVUCfh3buDItdQEEqLE0cHpWjM7Fp0k-6fV-dVYtrVf6Tf1zZ1_J_1gVroFdsUv2HyzbPBQuwDnYF45gYTjeyMZebnxavz7BLg-7mXVRm-1zsBz-eeqA8q9nNrQQXMU1jVG2yYeKY1-EDUtjrrrR6odOYXZ7y55OCWFklyb0E34PnNEyLu5a7akN24Iu1w3DL-x8uuGZb4uZu1DBg-I3S3U0HB5J6R3EyexSbdcmZKxNBL7NGAqgepdqPcWWvEw4G0y6HOylegPWZJdQuVdzCs4ZPha7iJ_xjXSA0airylnaerc4o7_l9JqliJAE4eAKh1Y49BbZY5BypH2y9_747MvXxq9DqucbmsJ_8jpVOPht87t_RjdRcboTsYzvkbsh1aDvPG7uk56dPyC3T8NiiodkHOFDPXxoAx8K8KENfGiAD53OKcCHtvChC0cRPpTRCJVH5Pzj8Xg4SsImG0mNuX9iS6eMBKp3BgIVnWZO5FbJ1MhcMGsEE7aQqtal0AMhc8eZGYjUDkxZlKV1lj8m_TkA6QmhNXgHa4VwOLfNixJcA6oFFqrOBNO63iev4sup6qBAjxuhzKq_jLBPXja3_vCyK7tuOoxvuIozFe1JnleyQvg8vcmzDsidFsDPSH-1XNvnEG6u9IuAg99ZPnyi |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+Immune+Mediators+and+Lifestyle+Changes+in+the+Prevention+of+Type+2+Diabetes&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=Herder%2C+Christian&rft.au=Peltonen%2C+Markku&rft.au=Koenig%2C+Wolfgang&rft.au=Kra%CC%88ft%2C+Ilka&rft.date=2006-08-01&rft.issn=0012-1797&rft.eissn=1939-327X&rft.volume=55&rft.issue=8&rft.spage=2340&rft.epage=2346&rft_id=info:doi/10.2337%2Fdb05-1320&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_db05_1320 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon |